神经外科医师大会系统综述与循证指南:丘脑底核与苍白球内侧部脑深部电刺激治疗帕金森病患者的执行摘要
该指南由神经外科医师大会基于系统综述制定,针对帕金森病丘脑底核与苍白球内侧部脑深部电刺激的7个临床问题给出推荐。推荐涉及运动症状、多巴胺能药物减量、异动症、生活质量、神经认知、情绪及不良事件,证据等级均为Level I。
要点
- 双侧丘脑底核脑深部电刺激在改善运动症状方面至少不劣于苍白球内侧部,可考虑选择任一靶点(Level I)。
- 若主要目标是减少多巴胺能药物,应行双侧丘脑底核而非苍白球内侧部脑深部电刺激(Level I)。
- 若关注认知下降或抑郁风险,临床医生应考虑苍白球内侧部而非丘脑底核刺激(Level I)。
核心结论
- 双侧丘脑底核脑深部电刺激在改善帕金森病运动症状方面至少与苍白球内侧部同样有效,可考虑选择任一靶点(Level I)。
- 当主要目标是减少多巴胺能药物时,应行双侧丘脑底核而非苍白球内侧部脑深部电刺激(Level I)。
- 关于减少异动症的靶点选择,证据不足无法给出普遍推荐;但若不预期减少药物且目标是减轻「开」期异动症严重程度,应选择苍白球内侧部(Level I)。
- 在改善生活质量方面,无依据推荐某一个靶点优于另一个(Level I)。
- 若显著担心认知下降(特别是处理速度和工作记忆),临床医生应考虑苍白球内侧部而非丘脑底核脑深部电刺激,同时考虑其他手术目标(Level I)。
研究设计与样本
- 该指南由神经外科医师大会基于系统综述制定,针对帕金森病患者丘脑底核与苍白球内侧部脑深部电刺激的7个临床问题给出循证推荐。
主要发现
- 双侧丘脑底核脑深部电刺激在改善帕金森病运动症状(以UPDRS-III评分改善衡量)方面至少与双侧苍白球内侧部同样有效(Level I)。
- 当主要目标是减少多巴胺能药物时,双侧丘脑底核脑深部电刺激优于苍白球内侧部(Level I)。
- 关于减少异动症的靶点选择证据不足;若不预期减少药物且目标为减轻「开」期异动症严重程度,应选择苍白球内侧部(Level I)。
- 在改善生活质量方面,无依据推荐某一个靶点优于另一个(Level I)。
- 若显著担心认知下降(特别是处理速度和工作记忆),应考虑苍白球内侧部而非丘脑底核脑深部电刺激(Level I)。
关键数值与推荐
- 问题1推荐:鉴于双侧丘脑底核脑深部电刺激在改善运动症状方面至少不劣于苍白球内侧部,可考虑选择任一靶点(Level I)。
- 问题2推荐:当主要目标是减少多巴胺能药物时,应行双侧丘脑底核而非苍白球内侧部脑深部电刺激(Level I)。
- 问题3推荐:关于减少异动症的靶点选择证据不足;若不预期减少药物且目标为减轻「开」期异动症严重程度,应选择苍白球内侧部(Level I)。
- 问题4推荐:在改善生活质量方面,无依据推荐某一个靶点优于另一个(Level I)。
- 问题5推荐:若显著担心认知下降(特别是处理速度和工作记忆),临床医生应考虑苍白球内侧部而非丘脑底核脑深部电刺激,同时考虑其他手术目标(Level I)。
临床怎么用
- 对于帕金森病运动症状,可考虑选择丘脑底核或苍白球内侧部任一靶点行双侧脑深部电刺激(Level I)。
- 当主要手术目标是减少多巴胺能药物时,应行双侧丘脑底核而非苍白球内侧部脑深部电刺激(Level I)。
- 若不预期减少药物且目标为减轻「开」期异动症严重程度,应选择苍白球内侧部靶点(Level I)。
- 若显著担心认知下降(特别是处理速度和工作记忆),临床医生应考虑苍白球内侧部而非丘脑底核脑深部电刺激(Level I)。
- 若显著担心抑郁风险,临床医生应考虑苍白球刺激而非丘脑底核刺激(Level I)。
局限性
- 关于减少异动症的靶点选择,原文指出证据不足无法给出普遍推荐。
- 关于减少手术不良事件风险的靶点选择,原文指出证据不足无法推荐某一个靶点优于另一个。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
QUESTION 1: Is bilateral subthalamic nucleus deep brain stimulation (STN DBS) more, less, or as effective as bilateral globus pallidus internus deep brain stimulation (GPi DBS) in treating motor symptoms of Parkinson's disease, as measured by improvements in Unified Parkinson's Disease Rating Scale, part III (UPDRS-III) scores? RECOMMENDATION: Given that bilateral STN DBS is at least as effective as bilateral GPi DBS in treating motor symptoms of Parkinson's disease (as measured by improvements in UPDRS-III scores), consideration can be given to the selection of either target in patients undergoing surgery to treat motor symptoms. (Level I). QUESTION 2: Is bilateral STN DBS more, less, or as effective as bilateral GPi DBS in allowing reduction of dopaminergic medication in Parkinson's disease? RECOMMENDATION: When the main goal of surgery is reduction of dopaminergic medications in a patient with Parkinson's disease, then bilateral STN DBS should be performed instead of GPi DBS. (Level I). QUESTION 3: Is bilateral STN DBS more, less, or as effective as bilateral GPi DBS in treating dyskinesias associated with Parkinson's disease? RECOMMENDATION: There is insufficient evidence to make a generalizable recommendation regarding the target selection for reduction of dyskinesias. However, when the reduction of medication is not anticipated and there is a goal to reduce the severity of "on" medication dyskinesias, the GPi should be targeted. (Level I). QUESTION 4: Is bilateral STN DBS more, less, or as effective as bilateral GPi DBS in improving quality of life measures in Parkinson's disease? RECOMMENDATION: When considering improvements in quality of life in a patient undergoing DBS for Parkinson's disease, there is no basis to recommend bilateral DBS in 1 target over the other. (Level I). QUESTION 5: Is bilateral STN DBS associated with greater, lesser, or a similar impact on neurocognitive function than bilateral GPi DBS in Parkinson disease? RECOMMENDATION: If there is significant concern about cognitive decline, particularly in regards to processing speed and working memory in a patient undergoing DBS, then the clinician should consider using GPi DBS rather than STN DBS, while taking into consideration other goals of surgery. (Level I). QUESTION 6: Is bilateral STN DBS associated with a higher, lower, or similar risk of mood disturbance than GPi DBS in Parkinson's disease? RECOMMENDATION: If there is significant concern about the risk of depression in a patient undergoing DBS, then the clinician should consider using pallidal rather than STN stimulation, while taking into consideration other goals of surgery. (Level I). QUESTION 7: Is bilateral STN DBS associated with a higher, lower, or similar risk of adverse events compared to GPi DBS in Parkinson's disease? RECOMMENDATION: There is insufficient evidence to recommend bilateral DBS in 1 target over the other in order to minimize the risk of surgical adverse events. The full guideline can be found at: https://www.cns.org/guidelines/deep-brain-stimulation-parkinsons-disease.
引用
- Rughani A, Schwalb JM, Sidiropoulos C, et al. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Subthalamic Nucleus and Globus Pallidus Internus Deep Brain Stimulation for the Treatment of Patients With Parkinson's Disease: Executive Summary. Neurosurgery. 2018. PMID: 29538685. doi:10.1093/neuros/nyy037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。